TY -的T1 -使用在线视觉模拟尺度特发性肺纤维化JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01531 -2021欧元SP - 2101531 AU -沼泽,Catharina c . AU - Mostard雷米L.M. AU -格拉特案的裁决,Jan c . AU -医学教授保罗盟——Wijsenbeek特发性肺纤维化(Idiopathic pulmonary fibrosis, IPF)是一种进行性、致命的疾病，严重影响患者的生活。症状负担和生活质量(QoL)可通过患者报告结局指标(PROMs)进行评估。在过去的十年中，越来越多的人提倡使用PROM来捕捉治疗和干预对患者症状和健康[2]的影响。PROMS通常是冗长的，在纸上，和困难的评分系统，阻碍了直接在临床实践[2]。因此，在IPF和其他ild中，有必要为临床试验和日常实践提供易于使用的prom。脚注本手稿最近已被接受发表在欧洲呼吸杂志。在我们的制作团队进行编辑和排版之前，它以接受的形式在这里发表。在这些生产过程完成后，作者已经批准了结果的证明，文章将移动到最新一期的ERJ在线。请打开或下载PDF以查看本文。利益冲突:C.C. Moor报告了勃林格殷格翰(Boehringer Ingelheim)在提交作品之外的拨款和演讲费用。Conflict of interest: Rémy Mostard reports personal fees from Boehringer Ingelheim, personal fees from Roche, personal fees from Galapagos, outside the submitted work.Conflict of interest: Jan Grutters and Paul Bresser have nothing to disclose.Conflict of interest: Marlies Wijsenbeek reports grant payments to institution from the Netherlands Organization for Health Research and Development during the conduct of the study; grant, contract payments, consulting fees, lecture payments and advisory board payments to institution from Boehringer Ingelheim, Hoffman la Roche, The Netherlands Organisation for Health Research and Development, The Dutch Lung Foundation, The Dutch Pulmonary Fibrosis Patient Association, The Thorax Foundation, ErasmusMC, Sarcoidosis.nl, Galapagos, Bristol Myers Squibb, Galecto, Respivant, Novartis, Savara; support for attending meetings from Boehringer Ingelheim and Hoffman la Roche; unpaid leadership roles: Secretary of the Idiopathic Interstitial Pneumonia group of the European Respiratory Society, Member of the board of the Netherlands Respiratory Society, Member of the scientific advisory board of the European Idiopathic Pulmonary Fibrosis and related disorders federation, Chair of the educational committee of the European Reference Network for rare Lung Diseases, Advisory board of the Dutch Lungfibrosis and Sarcoidosis patient associations, outside the submitted work. ER -